Already in 2013, Bhaskar and colleagues, based on their research, suggested the important role of angiopoietin in the etiology and course of MM and suggested ANGPT2 as a potential target for antiangiogenic therapy in the treatment of MM (60). The gene discussed is ANGPT2; the disease is Miyoshi myopathy.